Shionogi
SGIOYDrugs in Pipeline
38
Phase 3 Programs
18
Upcoming Catalysts
3
Next Catalyst
Jun 15, 2026
8wMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
Duloxetine Hydrochloride
Depressive Disorder
Ospemifene 60Mg Oral Tablet
Atrophy
Ospemifene (Dose 1)
Atrophy
Ospemifene 30 mg
Atrophy
Oral Glycopyrrolate Liquid
Cerebral Palsy
Meropenem
Healthcare-associated Pneumonia (HCAP)
Ospemifene 60 mg
Atrophy
Cefiderocol
Urinary Tract Infections
Ospemifene
Vaginal Dryness
Lusutrombopag
Chronic Liver Disease
S-217622
SARS-CoV-2 Infection
Baloxavir Marboxil
Influenza
CLONICEL (Clonidine HCl sustained release)
Attention Deficit Hyperactivity Disorder
S-268019-b
SARS-CoV-2
Pravafen
Combined Hyperlipidemia
Best Available Therapy
Healthcare-associated Pneumonia (HCAP)
Naldemedine
Opioid-induced Constipation
Oseltamivir
Influenza
Velneperit 400 mg
Obesity
S-2367 800 mg
Obesity
S-2367 1600 mg q.d. 54 Weeks
Obesity
Redasemtide
Acute Ischemic Stroke
S-606001
Pompe Disease
S-555739 Dose 1
Seasonal Allergic Rhinitis
BPN14770
Jordan's Syndrome
S-707106 Dose A
Type 2 Diabetes Mellitus
Sivopixant
Sleep Apnea
S-600918
Chronic Cough
S-309309
Obesity
50 mg S-777469
Atopic Dermatitis
S-892216
COVID-19
S-777469 400 mg
Atopic Dermatitis
S-2367 (velneperit)
Obesity
Ospemifene 5 mg
Atrophy
S-337395
Respiratory Syncytial Virus Infections
S-531011
Solid Tumors
S-3304
Non Small Cell Lung Cancer
Standard of Care
Gram-negative Bacterial Infections
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Duloxetine Hydrochloride | Phase 3 | Depressive Disorder | - | - |
Ospemifene 60Mg Oral Tablet | Phase 3 | Atrophy | - | - |
Ospemifene (Dose 1) | Phase 3 | Atrophy | - | - |
Ospemifene 30 mg | Phase 3 | Atrophy | - | - |
Oral Glycopyrrolate Liquid | Phase 3 | Cerebral Palsy | - | - |
Meropenem | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Ospemifene 60 mg | Phase 3 | Atrophy | - | - |
Cefiderocol | Phase 3 | Urinary Tract Infections | - | - |
Ospemifene | Phase 3 | Vaginal Dryness | - | - |
Lusutrombopag | Phase 3 | Chronic Liver Disease | - | - |
S-217622 | Phase 3 | SARS-CoV-2 Infection | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
CLONICEL (Clonidine HCl sustained release) | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
S-268019-b | Phase 3 | SARS-CoV-2 | - | - |
Pravafen | Phase 3 | Combined Hyperlipidemia | - | - |
Best Available Therapy | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Naldemedine | Phase 3 | Opioid-induced Constipation | - | - |
Oseltamivir | Phase 3 | Influenza | - | - |
Velneperit 400 mg | Phase 2 | Obesity | - | - |
S-2367 800 mg | Phase 2 | Obesity | - | - |
S-2367 1600 mg q.d. 54 Weeks | Phase 2 | Obesity | - | - |
Redasemtide | Phase 2 | Acute Ischemic Stroke | - | - |
S-606001 | Phase 2 | Pompe Disease | - | - |
S-555739 Dose 1 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
BPN14770 | Phase 2 | Jordan's Syndrome | - | - |
S-707106 Dose A | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Sivopixant | Phase 2 | Sleep Apnea | - | - |
S-600918 | Phase 2 | Chronic Cough | - | - |
S-309309 | Phase 2 | Obesity | - | - |
50 mg S-777469 | Phase 2 | Atopic Dermatitis | - | - |
S-892216 | Phase 2 | COVID-19 | - | - |
S-777469 400 mg | Phase 2 | Atopic Dermatitis | - | - |
S-2367 (velneperit) | Phase 2 | Obesity | - | - |
Ospemifene 5 mg | Phase 2 | Atrophy | - | - |
S-337395 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
S-531011 | Phase 2 | Solid Tumors | - | - |
S-3304 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Standard of Care | Phase 2 | Gram-negative Bacterial Infections | - | - |